InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
6
T+90 hit rate
0%
T+90 mean return
-10.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Johnson Craig A, Director. Director active across 5 companies, notably Heron Therapeutics, INC.. Aggregated, 18 reports have been recorded. Split: 0 buy · 6 sells. Total volume traded: €16k. History available since 21 June 2021. The latest transaction was disclosed on 31 January 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
17,950 shares0Common StockSEC:0000950170-25-013756:0
17,950 shares0Common StockSEC:0000950170-25-012101:0
20,631 shares0Common SharesSEC:0001600620-24-000122:0
6,021 sharesCommon StockSEC:0001140361-24-003534:0
13,948 shares0Common StockSEC:0001209191-24-001979:0
6,808 shares@ US$58.75100.0% of flowCommon StockSEC:0001628280-24-000321:0
4,444 shares0Common StockSEC:0001214659-23-001048:0
38,580 shares0Common StockSEC:0001209191-22-062188:0
12,000 shares@ US$6.2361.9% of flowCommon StockSEC:0000899243-22-029650:0
12,000 shares@ US$3.9338.1% of flowCommon StockSEC:0001209191-22-041988:0
2,546 shares0Common StockSEC:0001214659-22-000846:0
2,546 shares0Common StockSEC:0001214659-22-000846
250 shares@ US$9.72770.0009% mcap13.5% of flowCommon StockSEC:0001209191-21-071169:0
250 shares@ US$9.727713.5% of flowCommon StockSEC:0001209191-21-071169
250 shares@ US$12.29640.0011% mcap16.5% of flowCommon StockSEC:0001209191-21-057419:0
250 shares@ US$12.296416.5% of flowCommon StockSEC:0001209191-21-057419
250 shares@ US$15.202420.0% of flowCommon StockSEC:0001209191-21-042429
250 shares@ US$15.20240.0013% mcap20.0% of flowCommon StockSEC:0001209191-21-042429:0
18 of 18 declarations
About Johnson Craig A
Craig A. Johnson is a Board Member at HERON THERAPEUTICS, INC. and Mirati Therapeutics, Inc. He contributes to the strategic direction of these companies, participating in key decisions that influence their development. His expertise in the biopharmaceutical sector is valuable to the boards, enabling these companies to navigate effectively in a competitive environment.
